References
- Abbott, D. H., Barnett, D. K., Bruns, C. M., & Dumesic, D. A. (2005). Androgen excess fetal programming of female reproduction: A developmental aetiology for polycystic ovary syndrome? Human Reproduction Update, 11(4), 357–374. https://doi.org/https://doi.org/10.1093/humupd/dmi013
- Abbott, D. H., Dumesic, D. A., & Levine, J. E. (2019). Hyperandrogenic origins of polycystic ovary syndrome – Implications for pathophysiology and therapy. Expert Review of Endocrinology & Metabolism, 14(2), 131–143. https://doi.org/https://doi.org/10.1080/17446651.2019.1576522
- Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004). The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology and Metabolism, 89(6), 2745–2749. https://doi.org/https://doi.org/10.1210/jc.2003-032046
- Balen, A. H., Conway, G. S., Kaltsas, G., Techatrasak, K., Manning, P. J., West, C., & Jacobs, H. S. (1995). Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human Reproduction (Oxford, England), 10(8), 2107–2111. https://doi.org/https://doi.org/10.1093/oxfordjournals.humrep https://doi.org/https://doi.org/10.1093/oxfordjournals.humrep.a136243
- Barrett, E. S., Hoeger, K. M., Sathyanarayana, S., Abbott, D. H., Redmon, J. B., Nguyen, R. H. N., & Swan, S. H. (2018). Anogenital distance in newborn daughters of women with polycystic ovary syndrome indicates fetal testosterone exposure. Journal of Developmental Origins of Health and Disease, 9(3), 307–314. https://doi.org/https://doi.org/10.1017/S2040174417001118
- Bhide, P., & Homburg, R. (2016). Anti-Müllerian hormone and polycystic ovary syndrome. Best Practice & Research. Clinical Obstetrics & Gynaecology, 37, 38–45. https://doi.org/https://doi.org/10.1016/j.bpobgyn.2016.03.004
- Cresswell, J. L., Barker, D. J., Osmond, C., Egger, P., Phillips, D. I., & Fraser, R. B. (1997). Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet (London, England), 350(9085), 1131–1135. https://doi.org/https://doi.org/10.1016/s0140-6736(97)06062-5 https://doi.org/https://doi.org/10.1016/S0140-6736(97)06062-5
- Davies, M. J., March, W. A., Willson, K. J., Giles, L. C., & Moore, V. M. (2012). Birthweight and thinness at birth independently predict symptoms of polycystic ovary syndrome in adulthood. Human Reproduction (Oxford, England), 27(5), 1475–1480. https://doi.org/https://doi.org/10.1093/humrep/des027
- Deepika, M. L. N., Reddy, K. R., Rani, V. U., Balakrishna, N., Latha, K. P., & Jahan, P. (2013). Do ACE I/D gene polymorphism serve as a predictive marker for age at onset in PCOS? Journal of Assisted Reproduction and Genetics, 30(1), 125–130. https://doi.org/https://doi.org/10.1007/s10815-012-9906-8
- Detti, L., Jeffries-Boyd, H. E., Williams, L. J., Diamond, M. P., & Uhlmann, R. A. (2015). Fertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 32(12), 1749–1756. https://doi.org/https://doi.org/10.1007/s10815-015-0602-3
- Deugarte, C., Bartolucci, A., & Azziz, R. (2005). Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertility and Sterility, 83(5), 1454–1460. https://doi.org/https://doi.org/10.1016/j.fertnstert.2004.11.070
- Dewailly, D., Gronier, H., Poncelet, E., Robin, G., Leroy, M., Pigny, P., Duhamel, A., & Catteau-Jonard, S. (2011). Diagnosis of polycystic ovary syndrome (PCOS): Revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Human Reproduction (Oxford, England), 26(11), 3123–3129. https://doi.org/https://doi.org/10.1093/humrep/der297
- Ehrmann, D. A. (2005). Polycystic ovary syndrome. The New England Journal of Medicine, 352(12), 1223–1236. https://doi.org/https://doi.org/10.1056/NEJMra041536
- Eilertsen, T. B., Vanky, E., & Carlsen, S. M. (2012). Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Human Reproduction (Oxford, England), 27(8), 2494–2502. https://doi.org/https://doi.org/10.1093/humrep/des213
- Fabregues, F., Gonzalez-Foruria, I., Peñarrubia, J., & Carmona, F. (2018). Ovarian response is associated with anogenital distance in patients undergoing controlled ovarian stimulation for IVF. Human Reproduction, 33(9), 1696–1704. https://doi.org/https://doi.org/10.1093/humrep/dey244
- Georgopoulos, N. A., Papadakis, E., Armeni, A. K., Katsikis, I., Roupas, N. D., & Panidis, D. (2014). Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones (Athens, Greece), 13(2), 213–221. https://doi.org/https://doi.org/10.1007/BF03401335
- Hernández-Peñalver, A. I., Sánchez-Ferrer, M. L., Mendiola, J., Adoamnei, E., Prieto-Sánchez, M. T., Corbalán-Biyang, S., Carmona-Barnosi, A., Nieto, A., & Torres-Cantero, A. M. (2018). Assessment of anogenital distance as a diagnostic tool in polycystic ovary syndrome. Reproductive BioMedicine Online, 37(6), 741–749. https://doi.org/https://doi.org/10.1016/j.rbmo.2018.08.020
- Homburg, R., Gudi, A., Shah, A., & M Layton, A. (2017). A novel method to demonstrate that pregnant women with polycystic ovary syndrome hyper-expose their fetus to androgens as a possible stepping stone for the developmental theory of PCOS. A pilot study. Reproductive Biology and Endocrinology, 15(1), 61. https://doi.org/https://doi.org/10.1186/s12958-017-0282-1
- Homburg, R., Ray, A., Bhide, P., Gudi, A., Shah, A., Timms, P., & Grayson, K. (2013). The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Human Reproduction, 28(4), 1077–1083. https://doi.org/https://doi.org/10.1093/humrep/det015
- Jedel, E., Waern, M., Gustafson, D., Landen, M., Eriksson, E., Holm, G., Nilsson, L., Lind, A. K., Janson, P. O., & Stener-Victorin, E. (2010). Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Human Reproduction, 25(2), 450–456. https://doi.org/https://doi.org/10.1093/humrep/dep384
- Jones, M. R., & Goodarzi, M. O. (2016). Genetic determinants of polycystic ovary syndrome: Progress and future directions. Fertility and Sterility, 106(1), 25–32. https://doi.org/https://doi.org/10.1016/j.fertnstert.2016.04.040
- Kim, J. Y., Tfayli, H., Michaliszyn, S. F., Lee, S., Nasr, A., & Arslanian, S. (2017). Anti-Müllerian hormone in obese adolescent girls with polycystic ovary syndrome. Journal of Adolescent Health, 60(3), 333–339. https://doi.org/https://doi.org/10.1016/j.jadohealth.2016.10.015
- Lie Fong, S., Laven, J. S. E., Duhamel, A., & Dewailly, D. (2017). Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: Redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Human Reproduction (Oxford, England), 32(8), 1723–1731. https://doi.org/https://doi.org/10.1093/humrep/dex226
- Liu, C., Xu, X., & Huo, X. (2014). Anogenital distance and its application in environmental health research. Environmental Science and Pollution Research International, 21(8), 5457–5464. https://doi.org/https://doi.org/10.1007/s11356-014-2570-z
- Lizneva, D., Kirubakaran, R., Mykhalchenko, K., Suturina, L., Chernukha, G., Diamond, M. P., & Azziz, R. (2016). Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertility and Sterility, 106(6), 1510–1520.e2. https://doi.org/https://doi.org/10.1016/j.fertnstert.2016.07.1121
- Lujan, M. E., Chizen, D. R., & Pierson, R. A. (2008). Diagnostic criteria for polycystic ovary syndrome: Pitfalls and controversies. Journal of Obstetrics and Gynaecology Canada, 30(8), 671–679. https://doi.org/https://doi.org/10.1016/S1701-2163.
- Maliqueo, M., Lara, H. E., Sánchez, F., Echiburú, B., Crisosto, N., & Sir-Petermann, T. (2013). Placental steroidogenesis in pregnant women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 166(2), 151–155. https://doi.org/https://doi.org/10.1016/j.ejogrb.2012.10.015
- Palomba, S., Russo, T., Falbo, A., Di Cello, A., Tolino, A., Tucci, L., La Sala, G. B., & Zullo, F. (2013). Macroscopic and microscopic findings of the placenta in women with polycystic ovary syndrome. Human Reproduction, 28(10), 2838–2847. https://doi.org/https://doi.org/10.1093/humrep/det250
- Piouka, A., Farmakiotis, D., Katsikis, I., Macut, D., Gerou, S., & Panidis, D. (2009). Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: Relationship with increased luteinizing hormone levels . American Journal of Physiology. Endocrinology and Metabolism, 296(2), E238–E243. https://doi.org/https://doi.org/10.1152/ajpendo.90684.2008
- Quinn, M. M., Kao, C.-N., Ahmad, A. K., Haisenleder, D. J., Santoro, N., Eisenberg, E., Legro, R. S., Cedars, M. I., & Huddleston, H. G, NIH/NICHD Reproductive Medicine Network. (2017). Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold. Clinical Endocrinology, 87(6), 733–740. https://doi.org/https://doi.org/10.1111/cen.13415
- Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19(1), 41–47. https://doi.org/https://doi.org/10.1093/humrep/deh098
- Sahmay, S., Atakul, N., Aydogan, B., Aydın, Y., Imamoglu, M., & Seyisoglu, H. (2013). Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica, 92(12), 1369–1374. https://doi.org/https://doi.org/10.1111/aogs.12247
- Sahmay, S., Aydin, Y., Oncul, M., & Senturk, L. M. (2014). Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. Journal of Assisted Reproduction and Genetics, 31(2), 213–220. https://doi.org/https://doi.org/10.1007/s10815-013-0149-0
- Sánchez-Ferrer, M. L., Mendiola, J., Hernández-Peñalver, A. I., Corbalán-Biyang, S., Carmona-Barnosi, A., Prieto-Sánchez, M. T., Nieto, A., & Torres-Cantero, A. M. (2017a). Presence of polycystic ovary syndrome is associated with longer anogenital distance in adult Mediterranean women. Human Reproduction, 32(11), 2315–2323. https://doi.org/https://doi.org/10.1093/humrep/dex274
- Sánchez-Ferrer, M. L., Mendiola, J., Jiménez-Velázquez, R., Cánovas-López, L., Corbalán-Biyang, S., Hernández-Peñalver, A. I., Carmona-Barnosi, A., Maldonado-Cárceles, A. B., Prieto-Sánchez, M. T., Machado-Linde, F., Nieto, A., & Torres-Cantero, A. M. (2017b). Investigation of anogenital distance as a diagnostic tool in endometriosis. Reproductive BioMedicine Online, 34(4), 375–382. https://doi.org/https://doi.org/10.1016/j.rbmo.2017.01.002
- Sánchez-Ferrer, M. L., Prieto-Sánchez, M. T., Moya-Jiménez, C., Mendiola, J., García-Hernández, C. M., Carmona-Barnosi, A., Nieto, A., & Torres-Cantero, A. M. (2018). Anogenital distance and perineal measurements of the pelvic organ prolapse (POP) quantification system. Journal of Visualized Experiments, (139), 57912. https://doi.org/https://doi.org/10.3791/57912
- Sova, H., Unkila-Kallio, L., Tiitinen, A., Hippeläinen, M., Perheentupa, A., Tinkanen, H., Puukka, K., Bloigu, R., Piltonen, T., Tapanainen, J. S., & Morin-Papunen, L. (2019). Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. Gynecological Endocrinology, 35(7), 595–600. https://doi.org/https://doi.org/10.1080/09513590.2018.1559807
- Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., & Norman, R. J, International PCOS Network. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction (Oxford, England), 33(9), 1602–1618. https://doi.org/https://doi.org/10.1093/humrep/dey256
- Tuten, A., Sahmay, S., Oncul, M., Acikgoz, A. S., Imamoglu, M., Gurleyen, H. C., & Senturk, M. L. (2014). Serum AMH levels in the differential diagnosis of hyperandrogenemic conditions. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 177, 121–125. https://doi.org/https://doi.org/10.1016/j.ejogrb.2014.03.016
- Walters, K. A., Gilchrist, R. B., Ledger, W. L., Teede, H. J., Handelsman, D. J., & Campbell, R. E. (2018). New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends in Endocrinology and Metabolism, 29(12), 841–852. https://doi.org/https://doi.org/10.1016/j.tem.2018.08.005
- Wild, S., Pierpoint, T., McKeigue, P., & Jacobs, H. (2000). Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study. Clinical Endocrinology, 52(5), 595–600. https://doi.org/https://doi.org/10.1046/j.1365-2265.2000.01000.x
- Wu, Y., Zhong, G., Chen, S., Zheng, C., Liao, D., & Xie, M. (2017). Polycystic ovary syndrome is associated with anogenital distance, a marker of prenatal androgen exposure. Human Reproduction, 32(4), 1–943. https://doi.org/https://doi.org/10.1093/humrep/dex042